Study of Anthranylic Acid Derivatives: Mefenamic Acid and Its Various Analogues

Mohammad Asif^1,

¹Department of Pharmacy, GRD (PG) IMT, Dehradun, India

Cite this paper:
Mohammad Asif. Study of Anthranylic Acid Derivatives: Mefenamic Acid and Its Various Analogues. American Journal of Medicine Studies. 2014; 2(1):24-30. doi: 10.12691/ajms-2-1-4

Abstract

Anthranylic acid derivatives are direct structural analogs of salicylic acid derivatives. They possess analgesic, anti-inflammatory, and antipyretic activity. They are similar to pyrazolones in terms of analgesic and antipyretic activity, yet they exceed the anti-inflammatory activity of salicylates. The mechanism of action of this series of nonsteroid, anti-inflammatory analgesics is not conclusively known. One of the early advances in the search for nonnarcotic analgesics was centered in the N-arylanthranilic acids. The outstanding characteristic of mefenamic acid is primarily anti-inflammatory , and secondarily, some possess analgesic properties.

Keywords:
anthranylic acid derivatives analgesic anti-inflammatory antipyretic nonsteroid

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Charlier, C. and Michaux, C., Dual inhibiton of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti inflammatory drugs. Eur J Med Chem, 2003;38: 645-659.
[2]	Unangst, P. C. Connor, D. T. Centenko, W. A. Sorenson, R. J. Kostlan, R. K. Sircar, J. C. Wright, C. D. Schrier, D. J. and Dyer, R. D., Synthesis and biological evaluation of 5-[[3, 5-Bis (1,1-dimethylethyl)-4-hydroxyphenyl] methylene] oxazoles,-thiazoles and imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with anti inflammatory activity. J Med Chem, 1994; 37 322-328.
[3]	De Leval, X. Delarge, J. J. Pirotte, B. and Dogne, J. M., New trends in dual 5 LOX/COX inhibition. Curr Med Chem, 2003; 9: 941-962.
[4]	Lima, P. C. Lima, L.M. da Silva, K. C. M. Leda, P. H. O. de Miranda, A. L. P. Fraga, C. A. M. and Barreiro, E. J., Synthesis and analgesic activity of novel Nacylarylhydrazones and isosters, derived from natural safrole. Eur J Med Chem, 2000; 35: 187-203.
[5]	Figueiredo, J. M. Camara, C. A. Amarante, E. G. Miranda, A. L. P. Santos, F. M. Radrigues, C. R. Fraga, C. A. M. and Barreiro, E. J., Design and synthesis of novel potent antinociceptive Agents: Methyl-imidazolyl NAcylharazone derivatives. Bioorg Med Chem, 2000; 8: 2243-2248.
[6]	Boschelli, D. H. Connor, D. T. Bornemeier, D. A. Dyer, R. D. Kennedy, J. A. Kuipers, P. J. Okonkwo, G. C. Schrier, D. J. and Wright, C. D., 1,3,4-oxadiazole, 1, 3, 4- thiadiazole, and 1, 2, 4-triazole analogs of the fenamates: In vitro inhibition of cyclooxygenase and 5-lipoxygenase Activities. J Med Chem, 1993; 36: 1802-1810.
[7]	Soll AH, Weinstein WM, Kurata J et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991; 114:307-19.
[8]	Kar A. Analgesic and antipyretic. Chapter 10, Medicinal chemistry, New Age Publication. 2007, 294, 295, 301.
[9]	AHFS drug information . McEvoy GK, ed. Mefenamic acid. Bethesda, MD: American Society of Health-System Pharmacists; 2007:2096-9.
[10]	Vardanyan R.S. and Hruby V.J. Analgesics, Synthesis of Essential Drugs, Elsevier, 2006, Pages 19-55. ISBN: 978-0-444-52166-8.
[11]	Allais, A., Rousseau, G., Girault, P., et al. Sur l’activite´ analge´sique et anti inflammatoire des 4-(20-alcoxycarbonyl phe´nylamino) quinoleınes. Eur. J.Med Chem. 1966; 1: 65-70.
[12]	Aguiar, A.J. and Zelmer, J.E. Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J. Pharm. Sci. 1969;58: 983–987.
[13]	Dittert, L.W., Caldwell, H.C., Ellison, T., et al. Carbonate ester prodrugs of salicylic acid. J. Pharm. Sci. 1968; 57: 828–831.
[14]	Food and Drug Administration. Labeling revisions for NSAIDs. FDA Drug Bull. 1989; 19:3-4.
[15]	Searle. Cytotec (misoprostol) prescribing information. Skokie, IL; 1989 Jan.
[16]	US Food and Drug Administration. Proposed NSAID Package Insert Labeling Template 1. Accessed 10 Oct 2005.
[17]	Buchanan RA, Eaton CJ, Koeff ST et al. The breast milk excretion of mefenamic acid. Curr Ther Res Clin Exp. 1968; 10: 592-7.
[18]	Chan TY. Adverse interactions between warfarin and nonsteroidal antinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother. 1995; 29:1274-83.
[19]	Neuvonen PJ, Kivistö KT. Enhancement of drug absorption by antacids: an unrecognized drug interaction. Clin Pharmacokinet. 1994; 27:120-8.
[20]	Diana FJ, Veronich K, Kapoor AL. Binding of nonsteroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin. J Pharm Sci. 1989; 78: 195-9.
[21]	MacKenzie IZ, Graf AK, Mitchell MD. Prostaglandins in the fetal circulation following maternal ingestion of a prostaglandin synthetase inhibitor during mid-pregnancy. Int J Gynaecol Obstet. 1985; 23: 455-8.
[22]	American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis; 2002 update. Arthritis Rheum. 2002; 46:328-46.
[23]	Anon. Drugs for rheumatoid arthritis. Med Lett Drugs Ther. 2000; 42:57-64.
[24]	Nonsteroidal anti-inflammatory drug interactions: Lithium. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:608-9.
[25]	Miller LG, Bowman RC, Bakht F. Sparing effect of sulindac on lithium levels. J Fam Prac. 1989; 28:592-3.
[26]	Corticosteroid interactions: nonsteroidal anti-inflammatory drugs (NSAIDs). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:562.
[27]	Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343:769-72.
[28]	Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994; 96:274-81.
[29]	Schubert TT, Bologna SD, Yawer N et al. Ulcer risk factors: interaction between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med. 1993; 94:413-7.
[30]	Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991; 114:735-40.
[31]	Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients: the medicine may be worse than the disease. BMJ. 1995; 310:817-8.
[32]	Lithium interactions: diclofenac. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:607.
[33]	Hawkey CJ. COX-2 inhibitors. Lancet. 1999; 353:307-14.
[34]	Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384:644-8.
[35]	DeWitt DL, Bhattacharyya D, Lecomte M et al. The differential susceptibility of prostaglandin endoperoxide H synthases-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res. 1995; 5:325-43.
[36]	Riendeau D, Charleson S, Cromlish W et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmaco. 1997; 75:1088-95.
[37]	Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase—a review. Prostaglandins Other Lipid Mediators. 1998; 56:341-61.
[38]	Morrison BW, Daniels SE, Kotey P et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled study. Obstet Gynecol. 1999; 94:504-8.
[39]	Simon LS, Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999; 106(Suppl 5B):37-42S.
[40]	Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 2005 Apr 6.
[41]	Cush JJ. The safety of COX-2 inhibitors: deliberations from the February 16-18, 2005, FDA meeting. From the American College of Rheumatology website. Accessed 2005 Oct 12.
[42]	McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296: 1633-44.
[43]	Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332: 1302-5.
[44]	Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk; the seduction of common sense. JAMA. 2006; 296:1653-6.
[45]	Chou R, Helfand M, Peterson K et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4. (Prepared by the Oregon evidence-based practice center under contract no. 290-02-0024.). Rockville, MD: Agency for Healthcare Research and Quality. 2006 Sep.
[46]	Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888-99.
[47]	First Horizon Pharmaceutical Corporation. Ponstel (mefenamic acid) capsules prescribing information. Alpharetta, GA; 2006 Jan.
[48]	Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999; 26(suppl 56):18-24.
[49]	Lanza FL, and the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998; 93:2037-46.
[50]	Almasirad A, Tajik M, Bakhtiari D, Abdollahi ASM, Zamani MJ, Khorasani R, Esmaily H. Synthesis and analgesic activity of Narylhydrazone derivatives of mefenamic acid. J Pharm Pharmaceut Sci, 8(3):419-425, 2005.
[51]	Ribeiro, I. G. da Silva, K. C. M. parrini, S. C. de Miranda, A. L. P. Fraga, C. A. M. Barreiro, E. J., Synthesis and antinociceptive properties of new structurally planned imidazo [1, 2-a] pyridine 3-acylarylhydrazone derivatives. Eur J Med Chem, 1998; 33: 223-235.
[52]	Leite, L. F. C. C. Ramos, M. N. da Silva, J. B. P. Miranda, A. L. P. Fraga, C. A. M. and Barreiro, E. J.,Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1, 2, 4-oxadiazole-5-carbohydrazide. IL Farmaco, 1999; 54: 747-757.
[53]	Alfred, S. Fitzi, K. and Pfister, R., Analgesic cinnamic acid derivatives. South African Patent 6, 705, 990. 1963; Chem Abstr, 1969, 70, p 67938.
[54]	Al-Haboubi, H. A. Zeitlin, I. J., Re-appraisal of the role of histamine in carrageenan induced oedema. Eur J Pharmacol, 1983; 88: 160-176.